Prostatic Diseases and Male Voiding DysfunctionClinical Phenotyping of Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Correlation With Symptom Severity
Section snippets
Material and Methods
We reviewed the clinical records of 90 new patients with a diagnosis of CPPS seen at the Cleveland Clinic by 1 physician (D.A.S.) and whose information had been recorded in an institutional review board-approved database. Each patient had had their symptom severity measured using the National Institutes of Health Chronic Prostatitis Symptom Index (CPSI),4 reported as subscores for pain, urinary, and quality of life, as well as the total score. A review of the history, physical examination
Results
The mean patient age in this cohort was 44.3 years (range 21-71), with a median duration of symptoms of 30 months (range 3-444). The patients had CPSI scores typical of those reported by us in previous clinical studies: pain 10.8 ± 3.8 (range 0-20), urinary 4.4 ± 3.1 (range 0-10), quality of life 8.5 ± 2.6 (range 2-12), and total 23.7 ± 7.3 (range 6-42). The number of patients with positive findings for each domain was 47 (52%), 31 (34%), 55 (61%), 14 (16%), 33 (37%), and 48 (53%) for the
Comment
Patients with urologic chronic pelvic pain syndromes, including CPPS and interstitial cystitis, are a heterogeneous mix that share clinical features defined by their syndromes but have diverse etiologies and different responses to therapies. Currently, no biomarkers have been validated to help guide classification and treatment. In response to this, we have proposed a clinical phenotype classification in an attempt to better stratify patients with urologic CPPS according to the likely etiologic
References (17)
- et al.
Long-term results of multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome
J Urol
(2003) - et al.
Cytologic evaluation of urine is important in evaluation of chronic prostatitis
Urology
(2002) - et al.
The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure
J Urol
(1999) - et al.
Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis: the National Institutes of Health Chronic Prostatitis cohort study
J Urol
(2002) - et al.
Mechanisms in prostatitis/chronic pelvic pain syndrome
J Urol
(2008) - et al.
Catastrophizing and pain-contingent rest predict patient adjustment in men with chronic prostatitis/chronic pelvic pain syndrome
J Pain
(2006) - et al.
Clinical significance of nontraditional bacterial uropathogens in the management of chronic prostatitis
J Urol
(2008) - et al.
Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial
J Urol
(2003)
Cited by (0)
D. Shoskes is a paid consultant to Farr Labs and a stock holder in Triurol; J. C. Nickel has received grants/research support/scientific study from GlaxoSmithKlein, Merck, Ortho-McNeil, Stellar, Watson Pharmacueticals, Allergan, American Medical Systems, and Pfizer and is a consultant to Farr Laboratories, Merck-Frosst Canada, Ortho-McNeil, Glaxo-Smith-Kline, Triton Pharma, and Watson.